{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.2","upperLimit":"45.2","value":"35.2"},{"groupId":"OG001","lowerLimit":"37.8","upperLimit":"65.7","value":"51.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who have best response of Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). ORR per RECIST 1.1 as assessed by blinded independent central review (BICR) is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG000","title":"Recurrent or Metastatic Cutaneous cSCC Cohort"},{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG001","title":"Locally Advanced Unresectable cSCC Cohort"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 32 months","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}